Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Review, H1 2016', provides in depth analysis on Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted pipeline therapeutics. 

The report provides comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11)
- The report reviews Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) Overview 6
Therapeutics Development 7
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Stage of Development 7
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Therapy Area 8
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Indication 9
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Products under Development by Companies 12
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Companies Involved in Therapeutics Development 20
Novartis AG 20
Pharmaleads SA 21
Theravance Biopharma, Inc. 22
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Drug Profiles 23
(sacubitril + valsartan) - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
PL-265 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
PL-37 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
STR-324 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TD-0714 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Dormant Projects 35
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Discontinued Products 36
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or CD10 or EC 3.4.24.11) - Featured News & Press Releases 37
Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition 37
Apr 02, 2016: New analyses show Novartis' Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless 38
Mar 09, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin 38
Jan 20, 2016: Breakthrough drug for heart failure now available in the UK 39
Dec 08, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-0714, an Inhibitor of Neprilysin 40
Dec 02, 2015: New heart failure therapy projected to increase life expectancy 41
Nov 24, 2015: Novartis' heart failure medicine Entresto receives EU approval 42
Nov 10, 2015: Novartis heart failure medicine Entresto substantially cuts 30-day hospital readmissions, new post-hoc analysis shows 42
Oct 13, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-0714, an Inhibitor of Neprilysin 43
Oct 06, 2015: Heart failure treatment ENTRESTO (LCZ696) shown to reduce the risk of cardiovascular death and hospitalization approved by Health Canada 44
Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 45
Sep 25, 2015: Novartis' new heart failure medicine Entresto recommended by CHMP for EU approval 46
Sep 18, 2015: Swissmedic approves Novartis' new heart failure medicine Entresto 47
Jul 07, 2015: Novartis' new heart failure medicine LCZ696, now called Entresto, approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization 47
Jun 22, 2015: New Drug, LCZ696, Show Promise for Treating Your Heart Failure 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by Novartis AG, H1 2016 20
Pipeline by Pharmaleads SA, H1 2016 21
Pipeline by Theravance Biopharma, Inc., H1 2016 22
Dormant Projects, H1 2016 35
Discontinued Products, H1 2016 36